Company intelligence / Profile preview

StealthCo

Needham/Newton, Massachusetts, United Statesstealthco.co ↗

Ownership: Private
Employees: ~38
Development stage: Other

Overview

Lead candidate elamipretide has shown potential clinical benefit in rare genetic and common age-related ophthalmic and cardiac diseases. SBT‑272 is being evaluated for rare neurological disease indications including ALS. The company’s pipeline includes additional assets in preclinical development.

Therapeutic areas: Rare DiseasesCardiovascularOphthalmologyNeurology
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Collaborations with academic and medical institutions for advancing targeted therapies.

Beyond the preview

Go deeper on StealthCo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StealthCo.

Explore the full profile